- Home
- CDT vs GTBP Comparison
CDT vs GTBP Comparison
Compare CDT & GTBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CDT
- GTBP
- Stock Information
- Founded
- CDT 2019
- GTBP 1965
- Country
- CDT United States
- GTBP United States
- Employees
- CDT N/A
- GTBP N/A
- Industry
- CDT Biotechnology: Pharmaceutical Preparations
- GTBP Biotechnology: Pharmaceutical Preparations
- Sector
- CDT Health Care
- GTBP Health Care
- Exchange
- CDT Nasdaq
- GTBP Nasdaq
- Market Cap
- CDT 5.2M
- GTBP 5.6M
- IPO Year
- CDT N/A
- GTBP N/A
- Fundamental
- Price
- CDT $0.69
- GTBP $2.34
- Analyst Decision
- CDT
- GTBP Strong Buy
- Analyst Count
- CDT 0
- GTBP 1
- Target Price
- CDT N/A
- GTBP $11.00
- AVG Volume (30 Days)
- CDT 1.4M
- GTBP 33.2K
- Earning Date
- CDT 05-13-2025
- GTBP 05-14-2025
- Dividend Yield
- CDT N/A
- GTBP N/A
- EPS Growth
- CDT N/A
- GTBP N/A
- EPS
- CDT N/A
- GTBP N/A
- Revenue
- CDT N/A
- GTBP N/A
- Revenue This Year
- CDT N/A
- GTBP N/A
- Revenue Next Year
- CDT N/A
- GTBP N/A
- P/E Ratio
- CDT N/A
- GTBP N/A
- Revenue Growth
- CDT N/A
- GTBP N/A
- 52 Week Low
- CDT $0.65
- GTBP $1.72
- 52 Week High
- CDT $350.00
- GTBP $10.66
- Technical
- Relative Strength Index (RSI)
- CDT 31.97
- GTBP 52.62
- Support Level
- CDT $0.65
- GTBP $2.10
- Resistance Level
- CDT $1.05
- GTBP $2.45
- Average True Range (ATR)
- CDT 0.14
- GTBP 0.17
- MACD
- CDT 0.07
- GTBP -0.01
- Stochastic Oscillator
- CDT 7.30
- GTBP 73.86
About CDT Conduit Pharmaceuticals Inc.
Conduit Pharmaceuticals Inc is a clinical-stage specialty biopharmaceutical company that was formed to facilitate the development and commercialization of clinical assets that have not been or are not being, prioritized by biopharmaceutical companies to develop pharmaceutical products that meet the unmet medical needs of patients. The Company's current development pipeline includes a glucokinase activator, which is Phase II ready for autoimmune diseases including uveitis, Hashimoto's Thyroiditis, preterm labor, and renal transplant rejection. The Company's development pipeline also includes a potent, irreversible inhibitor of human Myeloperoxidase (MPO) that has the potential to treat idiopathic male infertility.
About GTBP GT Biopharma Inc.
GT Biopharma Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology products in the United States. It is engaged in discovering, developing, and commercializing novel therapeutics from its proprietary product platform in a varied range of disease areas. The company mainly develops drugs focused on the treatment of cancer. Its TriKE (Tri-specific Killer Engager) platforms offer immuno-oncology products that can treat a range of hematologic malignancies, sarcoma, and solid tumors.